News – Page 821 – Endpoints News

Praxis raises $110 million to target CNS disease with Phase II drugs

5 years ago

AbbVie backs an Italian startup focused on autoimmune diseases; BioTheryX advances AML drug with $35M D round

5 years ago

After stopping Farxiga trial early, AstraZeneca declares success in CKD treatment

5 years ago

A protein engineering platform spawns a new IL-2 player out of Basel, with human trials looming next summer

5 years ago

Distanced from a pricing controversy, Jeff Aronin steers one of his biotechs to Nasdaq — with a familiar regulatory ...

5 years ago

Pfizer/BioNTech makes surprise choice in final dash to October finish line for Covid-19 vaccine

5 years ago

Covid-19 roundup: Peter Kolchinsky’s RA Capital spearheads 'Covid Apollo,' a VC search for the best test; Upstart ...

5 years ago

After down year, 2020 brings new cash into Massachusetts biotech

5 years ago

House approves $3.2 billion FDA budget

5 years ago

Humanigen momentum barges on as Covid-19 candidate is selected for NIAID trial

5 years ago

Moderna begins first US pivotal Covid-19 vaccine study, lands $472M more from BARDA

5 years ago

Can progenitor cells go further than gene therapy in retinal disorders? A biotech's answer shines in PhIIb

5 years ago

Boehringer Ingelheim beefs up vet portfolio with GST buyout; Novartis, Austria to invest €150M in European ...

5 years ago

After Big Pharma abandoned infectious diseases, 5 biotech contrarians decided to go all in. Then Covid-19 changed ...

5 years ago

TCR² releases early data from some PhI patients, sparking optimism from analysts

5 years ago

Successful scientist-investor allies team up again — this time for a stab at rare metabolic disease

5 years ago

FDA keeps Solid Bio's troubled Duchenne MD gene therapy on clinical lockdown in latest setback

5 years ago

Covid-19 roundup: AstraZeneca builds $261M deal with US CDMO player for bulk Covid-19 vaccine supply; Corporate ...

5 years ago

AstraZeneca mines another $6B ADC from Daiichi Sankyo, with blockbuster ambitions to ‘redefine treatment ...

5 years ago

Trump looks to hammer down drug prices with 4 executive orders

5 years ago

Billionaire Dietmar Hopp steers his secretive Covid-19 biotech player to Nasdaq following major pact with GSK

5 years ago

Gilead’s Kite snares a landmark FDA OK on a $373,000 CAR-T therapy — which comes with bragging rights to the ...

5 years ago

Novartis, Gilead, GSK grab positive CHMPs; Menarini and Radius sign up to $350M partnership

5 years ago

Sobi's high-priority rare disease drug runs into a wall at EMA

5 years ago

First page Previous page 818 819 820821822 823 824 Next page Last page